RT Journal Article
SR Electronic
T1 A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP 1012
OP 1019
DO 10.1136/annrheumdis-2014-205207
VO 73
IS 6
A1 Laure Gossec
A1 Maarten de Wit
A1 Uta Kiltz
A1 Juergen Braun
A1 Umut Kalyoncu
A1 Rossana Scrivo
A1 Mara Maccarone
A1 Laurence Carton
A1 Kati Otsa
A1 Imre Sooäär
A1 Turid Heiberg
A1 Heidi Bertheussen
A1 Juan D Cañete
A1 Anselm Sánchez Lombarte
A1 Andra Balanescu
A1 Alina Dinte
A1 Kurt de Vlam
A1 Josef S Smolen
A1 Tanja Stamm
A1 Dora Niedermayer
A1 Gabor Békés
A1 Douglas Veale
A1 Philip Helliwell
A1 Andrew Parkinson
A1 Thomas Luger
A1 Tore K Kvien
A1 On behalf of the EULAR PsAID Taskforce
YR 2014
UL http://ard.bmj.com/content/73/6/1012.abstract
AB Introduction The objective was to develop a questionnaire that can be used to calculate a score reflecting the impact of psoriatic arthritis (PsA) from the patients’ perspective: the PsA Impact of Disease (PsAID) questionnaire. Methods Twelve patient research partners identified important domains (areas of health); 139 patients prioritised them according to importance. Numeric rating scale (NRS) questions were developed, one for each domain. To combine the domains into a single score, relative weights were determined based on the relative importance given by 474 patients with PsA. An international cross-sectional and longitudinal validation study was performed in 13 countries to examine correlations of the PsAID score with other PsA or generic disease measures. Test–retest reliability and responsiveness (3 months after a treatment change) were examined in two subsets of patients. Results Two PsAID questionnaires were developed with both physical and psychological domains: one for clinical practice (12 domains of health) and one for clinical trials (nine domains). Pain, fatigue and skin problems had the highest relative importance. The PsAID scores correlated well with patient global assessment (N=474, Spearman r=0.82–0.84), reliability was high in stable patients (N=88, intraclass correlation coefficient=0.94–0.95), and sensitivity to change was also acceptable (N=71, standardised response mean=0.90–0.91). Conclusions A questionnaire to assess the impact of PsA on patients’ lives has been developed and validated. Two versions of the questionnaire are available, one for clinical practice (PsAID-12) and one for clinical trials (PsAID-9). The PsAID questionnaires should allow better assessment of the patient's perspective in PsA. Further validation is needed.